Posted in Antibodies, Assay Kits, Biology Cells, cDNA, Clia Kits, Culture Cells, Elisa Kits, Enzymes, Equipments, Exosomes, Isotypes, Reagents, Recombinant Proteins, RNA, Test Kits
Comparison of different thawing protocols in human cryopreserved venous grafts.
The purpose of our study is to assess the impact of different disbursement protocols in morphological changes that arise in the grafting of cryopreserved human saphenous veins. This study was conducted on twelve saphenous vein grafts harvested on brain death donors. Storage in the liquid nitrogen phase for 3 or 5 years is followed. Two Disbursement Protocols are tested: 1. Giving birth in the refrigerator at + 4 ° C for 2 hours. 2. Fast Disbursement – In Tub Water at + 37 ° C. Graft is processed to scan an electron microscope. Comparison of continuous parameters in the study between experimental groups is carried out using T-Test (age, cold ischemic time, Cryoprotectant exposure, time of storage, total disbursement time, melting average, melted HSVG morphological assessment) and median test (HSVG length).
Categorical parameters (gender, blood group) are officially tested using the Chi-Square test. All samples are evaluated in accordance with morphological changes and scores in terms of mutually morphological endothelium, endothelum that supports structural inhomogenity, endothelial cell separation, separation, loss of endothelium and damage to the subendotial layer. There was no statistically significant difference between the sample set at a significance level of 0.05. There is no relationship with donor ages, gender and storage time. Graft Vena Saphenous Cryopreserved in our experimental work does not show the difference in terms of structural damage to endothelial surfaces and basal membranes depending on the liquefaction protocol used.
Cryopreserved human umbilical straps versus dermal acellular matrix patches for improving the Fetal Spina Bifida Fetal in the Pregnant Mouse Model.
Apart from a significant increase in the spinal cord function after the improvement of the Utero Spina Bifida (SB) compared to traditional postnatal improvements, more than half of the children who undergo this procedure did not benefit fully. The lack of benefits has been associated with the method of closing defects, with the next spinal cord tethering on the repair site. Therefore, regenerative fillings or materials with anti-inflammatory and anti-scar properties can relieve comorbidity with improved results.
Therefore the main goal of the author to compare the umbilical cable of the human cryopreserved (HUC) versus acellular dermal matrix (ADM) for regenerative repairs in the Uterero SB lesion in the animal model. In Vivo’s studies were carried out in the defect of SB which was induced by Retino acid in the Fetus of the Tikus Sprague-Dawley. Huc or ADM patches are sewn on the disability of SB at a 20 day gestation. The SB defective network that was repaired was harvested after 48-52 hours.
The network section is directed immunofluorescent to the existence of neutrophils, macrophages, keratinocytes, meningeal cells, and astrocytes and for related apoptosis. Experiments of cokultur meningeal cells or keratinocytes with ADM patch and HUC are carried out. All experiments are considered quantitatively in a blind manner. Nekrofil counts and lower apoptosis cells in the HUC-based improvement group (N = 8) rather than in the admin repair group (n = 7).
In the Huc Patch Repair Group, Keratinocytes are present on the outer surface of the patch, the meningeal cell is present on the surface of the inner surface adjacent to the neurlassode, and the astrocyte is not recorded. In the ADM patch repair group, all 3 types of cells are on both patch surfaces. In vitro studies show that human meningeal cells grow specially on the Mesenchymal Patch Huc side, while keratinocytes show tropism for the epithelial side, indicating the polarity based cells based. In contrast, ADM patch studies do not show the polarity and decrease in cellular infiltration.
A strong protocol for the free feeder adaptation of Cryopreserved pluripotent stem cells.
Human pluripotent stem cells (HPSCs) are managed conventionally in the embryon fibroblast feeder (MEF) mouse layer. However, downstream applications, such as directed differentiation protocols, are mainly optimized for Feeder-Free culture. Therefore, HPSCs must often be adapted to the free condition of the feeder. Here we propose a new free feeder adaptation protocol using Stemflex media, which can be directly applied to the liqueficible HPSC line. The free adaptation protocol of the feeder directly using Stemflex’s culture media in the Geltrex layer causes a strong HPSC culture in about 2 weeks.

This approach was tested with three human embryonic stem cell lines (HESC). All lines are confirmed to be pluripotent, expressing POU5F1, SOX2, and Nanog. No chromosome imbalance induced by the adaptation of feeder-free protocol is easily implemented in the laboratory that conducts a free culture of feeders, allowing more comfortable adaptation and stronger expansion of HPSC cryopreserved, even in cases when the sample quality is low or unknown.
The effects of human amniotic membranes cryopreserved on healing fracture: studies of animals.
The purpose of this study was to investigate the effects of human amniotic membranes (HAM) in healing fractures on animal models. Tibial diapial fractures can be created in twenty eight wistar-albino rats and treated with Kirschner intramedulller (K-Wire) wire and human rights (HAM (+)) or K-wire group (HAM (-)). Fracture healing is evaluated with histological analysis, radiological x-ray display and callus diameter measurement in 3 and 6 weeks postoperative postoperatively better in human rights group (+) and the difference is statistically significant in the 3rd and 6th week of post operation (p <0.05). The highest histological score and all the formation of woven bones (HUO Stage 8-9) was obtained in 6 weeks after surgery in the human rights group (+). Histological examination also revealed the dominant fibrous network and the formation of partial cartilage (HUO stage 2) in the 3rd week after surgery in the human rights group (-).
CD4+ T cells, Negatively Selected (Human) |
79752 |
BPS Bioscience |
10 million cells |
EUR 395 |
Description: Cryopreserved vial (10 x 10^6 cells) of CD4+ T cells that were negatively selected from freshly isolated primary human peripheral blood mononuclear cells (PBMCs). The PBMCs came from a healthy donor, and were isolated from whole blood or leukapheresis samples using a Ficoll gradient. Magnetic antibodies to monocytes, granulocytes, CD8+ T cells, gamma/delta T cells and other immune subsets present in PBMCs were then used to purify untouched CD4+ T cells via immunomagnetic separation. Before and after CD4+ T cell isolation, the cells were stained to evaluate purity and viability by flow cytometry. Cells were cryopreserved in CryoStor CS10 cryopreservation medium (Stemcell, #07930) at a controlled rate._x000D_Source Normal human PBMC from Leukapheresis Sample |
CD8+ T cells, Negatively Selected (Human) |
79753 |
BPS Bioscience |
10 million cells |
EUR 495 |
Description: Cryopreserved vial (10 x 10^6 cells) of CD8+ T cells that were negatively selected from freshly isolated primary human peripheral blood mononuclear cells (PBMCs). The PBMCs came from a healthy donor, and were isolated from whole blood or leukapheresis samples using a Ficoll gradient. Magnetic antibodies to monocytes, granulocytes, CD4+ T cells, gamma/delta T cells and other immune subsets present in PBMCs were then used to purify untouched CD8+ T cells via immunomagnetic separation. Before and after CD8+ T cell isolation, the cells were stained to evaluate purity and viability by flow cytometry. Cells were cryopreserved in CryoStor CS10 cryopreservation medium (Stemcell, #07930) at a controlled rate._x000D_Source Normal human PBMC from Leukapheresis Sample |
T-Pro Laemmli (SDS sample) Reagent (reducing 4X) |
JB06-F002 |
T-Pro Biotechnology |
10ml/BT |
EUR 151.2 |
T-Pro Nonliposomal Transfection Reagent I (NTR I) |
JT97-N001M |
T-Pro Biotechnology |
1.0ml/vial |
EUR 224.4 |
T-Pro Nonliposomal Transfection Reagent II (NTR II) |
JT97-N002M |
T-Pro Biotechnology |
1.0ml/vial |
EUR 244.8 |
T-Pro Nonliposomal Transfection Reagent III (NTR III) |
JT97-N006M |
T-Pro Biotechnology |
1.0ml/vial |
EUR 266.4 |
T-Pro Endotoxin Removal Plasmid Midi kit (25) |
RB94-EPI020 |
T-Pro Biotechnology |
20preps/Kit |
EUR 297.6 |
T-Pro Endotoxin Removal Plasmid Maxi kit (10) |
RB94-EPM010 |
T-Pro Biotechnology |
10preps/Kit |
EUR 318 |
T-Pro Laemmli (SDS sample) Reagent (non-reducing 4X) |
JB06-F003 |
T-Pro Biotechnology |
10ml/BT |
EUR 151.2 |
T-Pro LumiFast Plus Chemiluminescence Detection Kit (ECL Kit) |
JT96-K002M |
T-Pro Biotechnology |
250ml*2/Kit |
EUR 244.8 |
T-Pro LumiFast Plus Chemiluminescence Detection Kit (ECL Kit) |
JT96-K002S |
T-Pro Biotechnology |
100ml*2/Kit |
EUR 182.4 |
T-Pro LumiLong Plus Chemiluminescence Detection Kit (ECL Kit) |
JT96-K004M |
T-Pro Biotechnology |
250ml*2/Kit |
EUR 286.8 |
T-Pro LumiLong Plus Chemiluminescence Detection Kit (ECL Kit) |
JT96-K004S |
T-Pro Biotechnology |
100ml*2/Kit |
EUR 204 |
T-Pro Gel/PCR DNA Purification Maxi Kit (10) |
RB94-NEL010 |
T-Pro Biotechnology |
10preps/Kit |
EUR 193.2 |
T-Pro Gel/PCR DNA Purification Mini Kit (100) |
RB94-NES100 |
T-Pro Biotechnology |
100preps/Kit |
EUR 193.2 |
T-Pro Gel/PCR DNA Purification Mini Kit (250) |
RB94-NES250 |
T-Pro Biotechnology |
250preps/Kit |
EUR 266.4 |
T-Pro Washing buffer in PBS and Tween-20 (10X) |
JB09-I003 |
T-Pro Biotechnology |
500ml/BT |
EUR 172.8 |
T-Pro Washing buffer in TBS and Tween-20 (10X) |
JB09-I004 |
T-Pro Biotechnology |
500ml/BT |
EUR 172.8 |
T-Pro Phosphate-Buffered Saline (PBS, 10X) for western blot washing |
JB09-I001 |
T-Pro Biotechnology |
500ml/BT |
EUR 162 |
T-Pro Tris-Buffered Saline (TBS, 10X) for western blot washing |
JB09-I002 |
T-Pro Biotechnology |
500ml/BT |
EUR 162 |
Untransduced T Cells |
78170-1 |
BPS Bioscience |
1 vial |
EUR 1250 |
Description: The untransduced T cells are produced by mock lentiviral transduction of human primary CD4+CD8+ T cells. These cells are subjected to comparable manipulations as CAR-T cells: activation, spinoculation (without lentivirus), and expansion. These T cells are meant to be negative controls in experiments using lentivirus-transduced primary CAR-T cells. |
Untransduced T Cells |
78170-2 |
BPS Bioscience |
5 vials |
EUR 3325 |
Description: The untransduced T cells are produced by mock lentiviral transduction of human primary CD4+CD8+ T cells. These cells are subjected to comparable manipulations as CAR-T cells: activation, spinoculation (without lentivirus), and expansion. These T cells are meant to be negative controls in experiments using lentivirus-transduced primary CAR-T cells. |
Human Normal Peripheral Blood CD4+/CD25+ Regulatory T Cells (T reg), Fresh |
PBCD4-25-F2M |
101Bio |
- |
Ask for price |
Human Normal Peripheral Blood CD4+/CD25+ Regulatory T Cells (T reg), Cryopreserved |
PBCD4-25-C2M |
101Bio |
- |
Ask for price |
Human Cord Blood CD34+ Cells Derived Endothelial Cells |
HEC23 |
Neuromics |
500,000+ Cells |
EUR 1296 |
Anti-CD19 CAR-T Cells |
78171-1 |
BPS Bioscience |
1 vial |
EUR 1595 |
Description: The anti-CD19 CAR-T cells are produced by high-titer lentiviral transduction of human primary CD4+CD8+ T cells using the anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ; SIN Vector, BPS Bioscience, #78601). These ready-to use CAR-T cells express an anti-CD19 CAR consisting the ScFv of CD19 (clone FMC63) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains. These CAR-T cells have been validated using flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays. |
Anti-CD19 CAR-T Cells |
78171-2 |
BPS Bioscience |
5 vials |
EUR 4250 |
Description: The anti-CD19 CAR-T cells are produced by high-titer lentiviral transduction of human primary CD4+CD8+ T cells using the anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ; SIN Vector). These ready-to use CAR-T cells express an anti-CD19 CAR consisting the ScFv of CD19 (clone FMC63) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains.These CAR-T cells have been validated using flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays. |
Anti-BCMA CAR-T Cells |
78660-1 |
BPS Bioscience |
1 vial |
EUR 1595 |
Description: The anti-BCMA CAR-T cells are produced by high-titer lentiviral transduction of human primary CD4+CD8+ T cells using the anti-BCMA CAR Lentivirus (BPS Bioscience #78655). These ready-to-use CAR-T cells express an anti-BCMA CAR consisting of the ScFv of BCMA (clone C11D5.3) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains (Figure 1). These CAR-T cells have been validated using flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays. |
Anti-BCMA CAR-T Cells |
78660-2 |
BPS Bioscience |
5 vials |
EUR 4250 |
Description: The anti-BCMA CAR-T cells are produced by high-titer lentiviral transduction of human primary CD4+CD8+ T cells using the anti-BCMA CAR Lentivirus (BPS Bioscience #78655). These ready-to-use CAR-T cells express an anti-BCMA CAR consisting of the ScFv of BCMA (clone C11D5.3) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains (Figure 1). These CAR-T cells have been validated using flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays. |
anti-CD4 T helper cells |
502-A-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: anti-CD4 T helper cells |
anti-CD4 T helper cells |
502-A-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: anti-CD4 T helper cells |
anti-CD4 T helper cells |
502-A-100ugvial |
Virogen |
100 ug/vial |
EUR 150 |
|
Description: anti-CD4 T helper cells |
Human T- cell- interacting, activating receptor on myeloid cells |
ELI-41653h |
Lifescience Market |
96 Tests |
EUR 988.8 |
Immortalized Human Mucosal Associated Invariant T Cells (EM-C5) |
T0706 |
ABM |
1x106 cells / 1.0 ml |
Ask for price |
Immortalized Human Mucosal Associated Invariant T Cells (JK-A8) |
T0708 |
ABM |
1x106 cells / 1.0 ml |
Ask for price |
Immortalized Human Mucosal Associated Invariant T Cells (MG-A4) |
T0709 |
ABM |
1x106 cells / 1.0 ml |
Ask for price |
Immortalized Human Mucosal Associated Invariant T Cells (EM-B11) |
T0705 |
ABM |
1x106 cells / 1.0 ml |
Ask for price |
Immortalized Human Mucosal Associated Invariant T Cells (IK-B12) |
T0707 |
ABM |
1x106 cells / 1.0 ml |
Ask for price |
Human Schwann Cells |
HMP303 |
Neuromics |
500,000 Cells - Frozen |
EUR 1420.8 |
anti-CD8 T cytotoxic/supressor cells |
505-A-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: anti-CD8 T cytotoxic/supressor cells |
anti-CD8 T cytotoxic/supressor cells |
505-A-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: anti-CD8 T cytotoxic/supressor cells |
anti-CD8 T cytotoxic/supressor cells |
505-A-100ugvial |
Virogen |
100 ug/vial |
EUR 150 |
|
Description: anti-CD8 T cytotoxic/supressor cells |
Human Nuclear factor of activated T- cells 5, NFAT5 ELISA KIT |
ELI-39512h |
Lifescience Market |
96 Tests |
EUR 988.8 |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC942884-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF594 conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC942884-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF594 conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC802884-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF680 conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC802884-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF680 conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC702884-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF770 conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC702884-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF770 conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC882884-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF488A conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC882884-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF488A conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC812884-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF680R conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC812884-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF680R conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC402884-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF640R conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC402884-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF640R conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC052884-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF405M conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC052884-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF405M conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC042884-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF405S conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC042884-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF405S conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNCAP2884-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNCAP2884-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNCA2884-250 |
Biotium |
250uL |
EUR 472.8 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), APC conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNCP2884-250 |
Biotium |
250uL |
EUR 472.8 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), PerCP conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNCR2884-250 |
Biotium |
250uL |
EUR 472.8 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), RPE conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNCH2884-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNCH2884-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNCB2884-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), Biotin conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNCB2884-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), Biotin conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNUB2884-100 |
Biotium |
100uL |
EUR 316.8 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), Concentration: 0.2mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNUB2884-50 |
Biotium |
50uL |
EUR 486 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), 1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNUB2884-500 |
Biotium |
500uL |
EUR 615.6 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), Concentration: 0.2mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC472884-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF647 conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC472884-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF647 conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC552884-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF555 conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC552884-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF555 conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC612884-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF660R conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC612884-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF660R conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC432884-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF543 conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC432884-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF543 conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC682884-100 |
Biotium |
100uL |
EUR 279.6 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF568 conjugate, Concentration: 0.1mg/mL |
CD6 (Negative Marker of T-regulatory Cells) (C6/2884R) Antibody |
BNC682884-500 |
Biotium |
500uL |
EUR 654 |
Description: Primary antibody against CD6 (Negative Marker of T-regulatory Cells) (C6/2884R), CF568 conjugate, Concentration: 0.1mg/mL |
Human Melanoma antigen recognized by T- cells 1, MLANA ELISA KIT |
ELI-03589h |
Lifescience Market |
96 Tests |
EUR 988.8 |
Human T- cell surface glycoprotein CD3 zeta, CD247 ELISA Kit |
ELI-33983h |
Lifescience Market |
96 Tests |
EUR 988.8 |
Human Bone Marrow CD34+ Stem Cells, Fresh |
BMCD34-F0.5M |
101Bio |
- |
Ask for price |
Human Bone Marrow CD34+ Stem Cells, Fresh |
BMCD34-F5M |
101Bio |
- |
Ask for price |
Human Mesenchymal Stem Cells |
SC00A1 |
Neuromics |
500000 |
EUR 1086 |
CORNING®HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS, HUVEC-2 CELLS (>5X105 CELLS), 1 CRYOVIAL/PACK |
354151 |
CORNING |
1/pk |
EUR 465.6 |
Description: Permeable Support - DL; Coated Transwells - DL |
anti-CD38 Hematopoietic precursors, thymocytes, activated T-cells, plasma cells |
514-A-100ugvial |
Virogen |
100 ug/vial |
EUR 150 |
|
Description: anti-CD38 Hematopoietic precursors, thymocytes, activated T-cells, plasma cells |
Immortalized Human Colon Cells |
T0570 |
ABM |
1x106 cells / 1.0 ml |
Ask for price |
Human Nuclear factor of activated T cells, cytoplasmic 1(NFATC1) ELISA kit |
E01N0544-192T |
BlueGene |
192 tests |
EUR 1524 |
|
Description: A competitive ELISA for quantitative measurement of Human Nuclear factor of activated T cells, cytoplasmic 1(NFATC1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Human Nuclear factor of activated T cells, cytoplasmic 1(NFATC1) ELISA kit |
E01N0544-48 |
BlueGene |
1 plate of 48 wells |
EUR 624 |
|
Description: A competitive ELISA for quantitative measurement of Human Nuclear factor of activated T cells, cytoplasmic 1(NFATC1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Human Nuclear factor of activated T cells, cytoplasmic 1(NFATC1) ELISA kit |
E01N0544-96 |
BlueGene |
1 plate of 96 wells |
EUR 822 |
|
Description: A competitive ELISA for quantitative measurement of Human Nuclear factor of activated T cells, cytoplasmic 1(NFATC1) in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Immortalized Human Lingual Cells |
T0042 |
ABM |
1x106 cells / 1.0 ml |
Ask for price |
Immortalized Human Dendritic Cells |
T0525 |
ABM |
1x106 cells / 1.0 ml |
Ask for price |
Immortalized Human Mesangial Cells |
T0612 |
ABM |
1x106 cells / 1.0 ml |
Ask for price |
Jurkat Nuclear Extract (Acute T cell leukemia cells) |
NJKT-100 |
Alpha Diagnostics |
100 ug |
EUR 196.8 |
Jurkat Nuclear Extract (Acute T cell leukemia cells) |
NJKT-50 |
Alpha Diagnostics |
50 ug |
EUR 153.6 |
Human ES2 / GFP Stable Cells |
SC066-G |
GenTarget |
2 x 106 cell/ml x 1ml |
EUR 1800 |
Description: GFP expression stable cell line in Human ES2 cells with Puromycin resistance |
Human ES2 / RFP Stable Cells |
SC066-R |
GenTarget |
2 x 106 cell/ml x 1ml |
EUR 1800 |
Description: RFP expression stable cell line in Human ES2 cells with Puromycin resistance |
Normal Human Peripheral Blood Mononuclear Cells, Frozen -100 million cells |
79059-2 |
BPS Bioscience |
100 million cells |
EUR 580 |
Description: Cryopreserved vial (30 x 10^6 cells) of freshly isolated primary human peripheral blood mononuclear cells (PBMCs) from a healthy donor, isolated from leukapheresis / apheresis samples using Ficoll gradient. After isolation, the PBMCs were stained to identify sub populations and evaluated for viability by flow cytometry. Cells were cryopreserved in serum-free Cryostor CS10 at a controlled rate. |
Immortalized Human Testicular Cells |
T0603 |
ABM |
1x106 cells / 1.0 ml |
Ask for price |
Immortalized Human Urothelial Cells |
T0619 |
ABM |
1x106 cells / 1.0 ml |
Ask for price |
Immortalized Mouse CD4+ CD8+ T Cells (MOHITO) |
T0131 |
ABM |
1x106 cells / 1.0 ml |
Ask for price |
Human Bone Marrow CD34+ Stem Cells, Cryopreserved |
BMCD34-C0.5M |
101Bio |
- |
Ask for price |
Human Bone Marrow CD34+ Stem Cells, Cryopreserved |
BMCD34-C1M |
101Bio |
- |
Ask for price |
Human Bone Marrow CD34+ Stem Cells, Cryopreserved |
BMCD34-C5M |
101Bio |
- |
Ask for price |
Immortalized Human Oropharyngeal Cells |
T0041 |
ABM |
1x106 cells / 1.0 ml |
Ask for price |
anti-Transferrin receptor on activated T-B- cells |
518-A-01mg |
Virogen |
0,1 mg |
EUR 321 |
|
Description: anti-Transferrin receptor on activated T-B-, cells |
anti-Transferrin receptor on activated T-B- cells |
518-A-1000ug |
Virogen |
1000 ug |
EUR 1539 |
|
Description: anti-Transferrin receptor on activated T-B-, cells |
The number of woven bones and the formation of the same cartilage (Huo Stage 6-7) was observed in the 3rd week after surgery in the human rights group (+) and at 6 weeks after human rights operations (-). The diameter of the callus was larger in the human rights group (+) and the difference was statistically significant (P <0.05) at 3 and 6 weeks after surgery. Although there were only statistically significant differences (P <0.05) in the 3rd week after surgery, the radiological score tended to be higher in the human rights group (+) in both weeks and 6th week after surgery. Cheap alternatives and easily accessible biological materials. Human rights can be used to support the treatment of fracture surgery, especially where bone healing is expected to last longer.